LENZ Therapeutics (LENZ) Net Equity Issued and Repurchased (2020 - 2025)
LENZ Therapeutics (LENZ) posted quarterly Net Equity Issued and Repurchased of $26.1 million for Q2 2025, up 832.53% year-over-year from $2.8 million in Q2 2024, and up 30805.88% quarter-over-quarter from -$85000.0 in Q4 2024.
LENZ Therapeutics (LENZ) Net Equity Issued and Repurchased (2020 - 2025) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Net Equity Issued and Repurchased for 5 consecutive years, with $26.1 million the latest figure, recorded in Q2 2025.
- In Q2 2025, Net Equity Issued and Repurchased rose 832.53% year-over-year to $26.1 million; the TTM figure through Dec 2025 stood at $26.1 million (down 67.18% YoY), while the FY2024 annual figure was $79.5 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased improved to $26.1 million in Q2 2025 per LENZ's latest filing, from -$85000.0 in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $165.6 million in Q1 2021 and bottomed at -$83.0 million in Q3 2023.
- Historically, Net Equity Issued and Repurchased has averaged $30.3 million across 4 years, with a median of $21.5 million in 2023.
- Annual changes were most pronounced in 2024 — Net Equity Issued and Repurchased plunged 120.99% — and 2025, when it soared 832.53%.
- LENZ Therapeutics' Net Equity Issued and Repurchased stood at $14.8 million in 2021, then plunged by 659.85% to -$83.0 million in 2023, then jumped by 99.9% to -$85000.0 in 2024, then surged by 30805.88% to $26.1 million in 2025.
- Business Quant data shows LENZ's Net Equity Issued and Repurchased at $26.1 million in Q2 2025, -$85000.0 in Q4 2024, and $29.8 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | LENZ Therapeutics | 147.30 Mn | 147.30 Mn | 5.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 121.65 Mn |
| Dec 31, 2025 | 121.65 Mn |
| Sep 30, 2025 | 33,000.00 |
| Sep 30, 2025 | 33,000.00 |
| Jun 30, 2025 | 26.10 Mn |
| Jun 30, 2025 | 26.10 Mn |
| Dec 31, 2024 | -85,000.00 |
| Dec 31, 2024 | -85,000.00 |
| Sep 30, 2024 | 29.77 Mn |
| Sep 30, 2024 | 29.77 Mn |
| Jun 30, 2024 | -3.56 Mn |
| Jun 30, 2024 | -3.56 Mn |
| Mar 31, 2024 | 53.39 Mn |
| Mar 31, 2024 | 53.39 Mn |
| Sep 30, 2023 | -82.98 Mn |
| Sep 30, 2023 | -82.98 Mn |
| Jun 30, 2023 | 16.98 Mn |
| Jun 30, 2023 | 16.98 Mn |
| Mar 31, 2023 | 82.98 Mn |
| Mar 31, 2023 | 82.98 Mn |